Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced positive results from a Phase 2 investigator-sponsored clinical trial of felzartamab for late antibody-mediated rejection in kidney transplant recipients.
